Drugs · acquisition-cost intelligence
Aspirin
· ingredient aspirinOther agents for local oral treatment· ASPIRIN 325 mg/1; ASPIRIN 325 mg/3251
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.02233
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other aspirin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| adult low dose aspirin | $0.01438 | −$0.00790 |
| Aspirin | $0.01601 | −$0.00630 |
| Adult Chewable Aspirin | $0.02595 | +$0.00360 |
| AeroTab Pain Reliever | $0.04346 | +$0.02110 |
| ACETAMINOPHEN ASPIRIN AND CAFFEINE | $0.06716 | +$0.04480 |
| Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg | $0.57275 | +$0.55040 |
| butalbital, aspirin, and caffeine | $0.97831 | +$0.95600 |
| Ascomp with Codeine | $1.09 | +$1.06 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.